Nippon Kayaku acquires shares of a newly established company succeeding part of Fuji Pharma\u2019s pharmaceutical manufacturing business, making it a subsidiary. The business with sales of approximately 3 billion yen is scheduled to be succeeded on October 1, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4272","jir_company_name":"Nippon Kayaku Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4272-20260330-01.pdf","jir_short_summary":"Nippon Kayaku acquires shares of a newly established company succeeding part of Fuji Pharma\u2019s pharmaceutical manufacturing business, making it a subsidiary. The business with sales of approximately 3 billion yen is scheduled to be succeeded on October 1, 2026.","jir_summary":"### Overview of M&A\nNippon Kayaku Co., Ltd. resolved to acquire all shares of a newly established company succeeding part of Fuji Pharma Co., Ltd.'s pharmaceutical manufacturing business and convert it into a subsidiary, and concluded a share transfer agreement. The targeted business mainly involves contract development and manufacturing of prescription pharmaceuticals (injectables) at the Toyama Second Factory, scheduled to be succeeded through an absorption-type company split on October 1, 2026. The new company\u2019s sales are approximately 3 billion yen (forecast for fiscal year ending March 2026), with capital of 1 million yen and 5,000 shares issued.\n\n### Future Outlook and Impact\nThe impact on consolidated financial results for the fiscal year ending March 2026 from this share acquisition is expected to be minimal. However, in the medium to long term, strengthening the stable supply system and expanding production capacity for anticancer drugs and biosimilars is expected to contribute to business growth and enhanced corporate value. The board resolution and share transfer agreement conclusion date is March 30, 2026; the new company establishment date is April 30, 2026; and the share transfer date is scheduled for October 1, 2026.","jir_financial_highlights":"Sales of the acquired company: Approx. 3 billion yen (Forecast for fiscal year ending March 2026) (Unknown)\nCapital of the acquired company: 1 million yen (Unknown)\nNumber of shares of the acquired company: 5,000 shares (Unknown)","jir_category":"","jir_hashtags":"#NipponKayakuCoLtd, #M&A, #PharmaceuticalManufacturingBusiness, #Subsidiarization, #JapaneseStocks","jir_key_figures":"Sales: Approx. 3 billion yen (Forecast for fiscal year ending March 2026)\nCapital: 1 million yen\nNumber of shares: 5,000 shares","jir_meta_title":"Nippon Kayaku to Succeed Pharmaceutical Manufacturing Subsidiary of Fuji Pharma with Approx. 3 Billion Yen in Sales","jir_meta_description":"Nippon Kayaku Co., Ltd. acquires shares of a newly established company succeeding part of Fuji Pharma's pharmaceutical manufacturing business and makes it a subsidiary. Business succession scheduled for October 1, 2026, aiming for medium- to long-term business growth and corporate value enhancement.","jir_og_title":"Nippon Kayaku Announces Subsidiarization of Fuji Pharma\u2019s Pharmaceutical Manufacturing Business","jir_og_description":"Nippon Kayaku acquires shares of a newly established company succeeding part of Fuji Pharma\u2019s pharmaceutical manufacturing business, planned to become a subsidiary in October 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8762,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-37855","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n